One analyst takeaway from Shire’s 2018 outlook: Consensus earnings estimates probably need to come down. On Wednesday, the company said it was predicting $14.90 to $15.50 per share, a range that sits below the $15.94 Wall Street had been expecting. And that “initial 2018 outlook suggests EPS needs trimming,” Jefferies’ Peter Welford wrote in a note to clients.Original Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.